WEBULL
WebtradeDownload

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Simply Wall St · 1d ago

Ionis Pharmaceuticals (IONS) drew investor attention after its latest share price of US$57.24, with recent returns mixed over the past month and past 3 months as traders reassessed the RNA focused biotech story.

See our latest analysis for Ionis Pharmaceuticals.

The recent 1 month share price return of 5.24% comes after a 3 month share price decline of 21.07%, while the 1 year total shareholder return of 30.74% shows that Ionis Pharmaceuticals has rewarded patient holders even as shorter term momentum has faded.

If you are scanning beyond Ionis Pharmaceuticals for other healthcare ideas linked to advanced drug development, it can be useful to see which companies screen well in RNA and AI driven therapeutics using the 42 healthcare AI stocks

Ionis Pharmaceuticals has pulled back sharply over 3 months yet still sits on strong 1 year gains, which leaves a simple question for you as a shareholder or potential buyer: Does the current price still offer a favourable trade off between risk and reward?

Most Popular Narrative: 37.8% Undervalued

Ionis Pharmaceuticals is trading at $57.24 while the most followed narrative pegs fair value at $92.00. This frames the recent pullback as a valuation gap story rather than a momentum one.

The analysts have a consensus price target of $92.0 for Ionis Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $125.0, and the most bearish reporting a price target of just $66.0.

Read the complete narrative.

Curious what has to happen for Ionis Pharmaceuticals to line up with that fair value view? The narrative leans on rapid revenue expansion, a sharp swing into profitability and a rich future earnings multiple. The exact mix of growth, margins and discount rate assumptions is doing the heavy lifting here, and it is worth seeing how each piece fits together before you decide how that compares with your own expectations.

Result: Fair Value of $92.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ionis Pharmaceuticals still faces real pressure from potential pricing cuts as Olezarsen targets broader populations, as well as from any further late stage trial setbacks that hit key programs.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Next Steps

The narrative around Ionis Pharmaceuticals is cautiously optimistic, but the real question is how it fits with your own risk tolerance and return goals. Take a moment to review the same reward signals that many investors are watching by checking the 3 key rewards.

Looking for more investment ideas beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals is on your radar, you do not want to stop here. Broaden your watchlist now and give yourself more options for your next move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.